{
  "pmcid": "6868305",
  "sha256": "661077f7ac1b11807998c84ab0ea5b2f5a7668a95e70f6d705e6b1babd7cbb9b",
  "timestamp_utc": "2025-11-09T16:10:55.301509+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 11.722816793893134,
    "reading_ease": 34.34842366412215,
    "word_count": 262
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "A multicenter, cooperative group, single-arm phase II trial"
      },
      "Participants": {
        "score": 2,
        "evidence": "Patients with biopsy-confirmed PDAC in the pancreatic head without evidence of involvement of major mesenteric vessels (resectable) were eligible."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Patients (n=123) received an eight-week cycle of G+E before and after surgery."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study evaluated perioperative gemcitabine + erlotinib (G+E) for resectable PDAC."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary endpoint was two-year overall survival (OS)"
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "Patients (n=123) received an eight-week cycle of G+E before and after surgery."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "One hundred fourteen patients were eligible, consented, and initiated protocol treatment."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "The two-year OS rate for the entire cohort (n=114) was 40% (95%CI 31–50) with a median OS of 21.3 months (95%CI 17.2–25.9)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Grade 3+ toxicity was reported in 60% and 79% of patients during the neoadjuvant phase and overall, respectively."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "(ACOSOG Z5041)"
      },
      "Funding": {
        "score": 0,
        "evidence": "Not reported"
      }
    },
    "total_score": 16,
    "max_score": 25
  }
}